Corporate Banner
Satellite Banner
Scientific Community
Become a Member | Sign in
Home>News>This Article

Singapore Scientists Identify New Biomarker for Cancer in Bone Marrow

Published: Friday, December 14, 2012
Last Updated: Friday, December 14, 2012
Bookmark and Share
This discovery may potentially cure patients of multiple myeloma.

Singapore scientists have identified FAIM, a molecule that typically prevents cell death, as a potential biomarker to identify an incurable form of cancer in the bone marrow.

Patients with this form of cancer usually do not get cured with current standard treatments such as chemotherapy and stem cell transplantation, with an average survival of only about four years.

FAIM could thus be a therapeutic target in these patients, as drugs developed to target the molecule could destroy multiple myeloma cells and hence eradicate the cancer.

Multiple myeloma is an incurable cancer of blood cells, which arises due to an uncontrollable accumulation of antibody-producing plasma cells in the bone marrow.

In Singapore, about 80 new cases of multiple myeloma are diagnosed every year. Unfortunately, most people who develop multiple myeloma have no clearly identifiable risk factors for the disease but factors such as individuals older than 50 years of age, men and obesity, may predispose one to the cancer.

The scientists discovered that a protein called Fas apoptosis inhibitory molecule (FAIM) can affect the activation of Akt, an important enzyme required for cancer cell proliferation.

By silencing the expression of FAIM, the team showed that the myeloma cells could be destroyed. It was also found that this protein was present at higher levels in the plasma cells of these patients as compared to normal individuals, and that higher levels of FAIM correlated to poorer survival outcomes of patients.

This is an important breakthrough as it not only identifies FAIM as a useful biomarker of multiple myeloma patients, but also as a good target that drugs can be developed for, in order to get rid of the cancer cells.

This collaborative research was conducted by scientists at A*STAR's Bioprocessing Technology Institute (BTI) led by Prof Lam Kong-Peng, along with clinician-scientists at National University Cancer Institute, Singapore (NCIS) and the Cancer Science Institute of Singapore (CSI Singapore) at the National University of Singapore. The research findings were published in Leukemia on 5 December 2012.

Prof Lam said, "This study adds onto previous studies in the institute demonstrating the utility of FAIM not only in biotechnology but now potentially in the clinic. It is a prime example of how a better understanding of FAIM protein function enables us to first use it to increase yield in biologics manufacturing, and now as a potential prognostic biomarker in the clinic for a deadly human disease such as multiple myeloma. This is really a translation from bench-to-bioreactor and bench-to-bedside."

"Treatment failure due to drug resistance is an important reason why patients with multiple myeloma have a poor outcome. In this study, we identified FAIM as a new biomarker that is associated with poor outcome as well as an important mediator of growth signals in myeloma cells that could lead to drug resistance. The detection of this biomarker will allow us to identify these high risk patients and possibly develop treatments that target FAIM to improve their outcome. This study also underlines the potential for collaborative work between A*STAR research institutes (BTI), CSI Singapore and the National University Cancer Institute of Singapore (NCIS) to perform research that may have significant impact on patients," said Associate Professor Chng Wee Joo, who is Senior Consultant Haematologist at the Department of Haematology-Oncology, NCIS and Senior Principal Investigator at CSI.

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

A*STAR Findings on Breast Cancer Hold Potential for New Treatments
Computational techniques to increase understanding of diseases and improve patient treatments.
Friday, October 30, 2015
Gene Associated with an Aggressive Breast Cancer Identified
Over-expressed gene in triple negative breast cancer offers new diagnostics for risk assessment.
Wednesday, December 03, 2014
Novel Gene Predicts Both Breast Cancer Relapse and Response to Chemotherapy
A predictive marker discovered by scientists at A*STAR and NUS could help doctors classify breast cancer patients for more effective treatment.
Thursday, August 21, 2014
New Tool to Study Critical Protein Interaction in Cancer Research
A*STAR scientists used fluorescent molecular rotors to study protein-protein interactions involving p53 and MDM2 in cells.
Thursday, July 03, 2014
New Possibilities for Leukaemia Therapy with a Novel Mode of Cancer Cell Recognition
A new class of lipids in human leukaemia cells trigger an immune response to kill the cells.
Thursday, June 26, 2014
Singapore Scientists Discover New RNA Processing Pathway Important in hESCs
Discovery of RNA regulator could lead to a better understanding of diseases like cancer and influenza.
Monday, September 09, 2013
Scientists at GIS Discover Gene that Controls the Birth of Neurons
Discovery of long non-coding RNA's role in neurogenesis may lead to cures for diseases such as Alzheimer's disease.
Thursday, August 29, 2013
A*STAR Scientist Alex Matter Awarded Prestigious Szent-Gyorgyi Prize For Progress In Cancer Research
National Foundation for Cancer Research honours Professor Alex Matter with esteemed award for groundbreaking cancer pill that gives leukaemia patients a new lease of life.
Friday, April 05, 2013
A*STAR's GIS Collaborates with GSK to Further Research on Lung Cancer
Partnership will advance both organizations' joint efforts towards finding a cure for the disease.
Thursday, January 31, 2013
A*STAR Scientists Discover Potential Drug for Deadly Brain Cancer
This discovery can potentially prevent the progression and relapse of deadly brain tumours.
Tuesday, January 15, 2013
A*STAR Scientists Identify Potential Drug Target for Inflammatory Diseases Including Cancers
This discovery holds the potential to reduce healthcare costs for many common inflammatory diseases such as cancer and diabetes.
Thursday, November 22, 2012
A*STAR Scientists Pinpoint Genetic Changes that Spell Cancer
Fruit flies light the way for scientists to uncover genetic changes.
Thursday, August 16, 2012
A*STAR Chief Scientist Wins Cancer Research UK Lifetime Achievement Prize
Professor Lane will receive the award at the National Cancer Research Institute Cancer Conference in Liverpool.
Thursday, July 19, 2012
Discovery of the Cellular Origin of Cervical Cancer
A team of scientists have identified a unique set of cells in the cervix that are the cause of HPV related cervical cancers.
Tuesday, June 12, 2012
A*STAR and GE Global Research Sign Memorandum of Understanding
Agreement to develop integrated advanced medical imaging technologies for improved clinical diagnosis.
Friday, April 13, 2012
Scientific News
Revolutionary Technologies Developed to Improve Outcomes for Lung Cancer Patients
Breath test to detect lung cancer brings oxygen directly to the wound.
New Class of RNA Tumor Suppressors Identified
Two short, “housekeeping” RNA molecules block cancer growth by binding to an important cancer-associated protein called KRAS. More than a quarter of all human cancers are missing these RNAs.
Mathematical Model Forecasts the Path of Breast Cancer
Chances of survival depend on which organs breast cancer tumors colonize first.
Exploring the Causes of Cancer
Queen's research to understand the regulation of a cell surface protein involved in cancer.
Nanocarriers May Carry New Hope for Brain Cancer Therapy
Berkeley lab researchers develop nanoparticles that can carry therapeutics across the brain blood barrier.
RNA-Based Drugs Give More Control Over Gene Editing
CRISPR/Cas9 gene editing technique can be transiently activated and inactivated using RNA-based drugs, giving researchers more precise control in correcting and inactivating genes.
University of Glasgow Researchers Make An Impact in 60 Seconds
Early-career researchers were invited to submit an engaging, dynamic and compelling 60 second video illuminating an aspect of their research.
Metabolic Profiles Distinguish Early Stage Ovarian Cancer with Unprecedented Accuracy
Studying blood serum compounds of different molecular weights has led scientists to a set of biomarkers that may enable development of a highly accurate screening test for early-stage ovarian cancer.
Dead Bacteria to Kill Colorectal Cancer
Scientists from Nanyang Technological University (NTU Singapore) have successfully used dead bacteria to kill colorectal cancer cells.
CRISPR-Cas9 Gene Editing: Check Three Times, Cut Once
Two new studies from UC Berkeley should give scientists who use CRISPR-Cas9 for genome engineering greater confidence that they won’t inadvertently edit the wrong DNA.

SELECTBIO Market Reports
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos